Oppenheimer Asset Management Inc. Grows Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Oppenheimer Asset Management Inc. raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,852 shares of the biotechnology company’s stock after purchasing an additional 547 shares during the period. Oppenheimer Asset Management Inc.’s holdings in United Therapeutics were worth $8,235,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its holdings in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. Access Investment Management LLC increased its holdings in shares of United Therapeutics by 0.8% in the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock worth $2,314,000 after buying an additional 55 shares during the period. MBM Wealth Consultants LLC increased its holdings in shares of United Therapeutics by 2.7% in the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock worth $515,000 after buying an additional 59 shares during the period. Fifth Third Bancorp increased its holdings in shares of United Therapeutics by 13.2% in the second quarter. Fifth Third Bancorp now owns 585 shares of the biotechnology company’s stock worth $186,000 after buying an additional 68 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of United Therapeutics by 3.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 2,666 shares of the biotechnology company’s stock worth $849,000 after buying an additional 81 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. TD Cowen raised their target price on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. UBS Group raised their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $350.36.

United Therapeutics Stock Performance

Shares of UTHR opened at $339.12 on Friday. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average price is $336.73 and its 200-day moving average price is $287.53. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $366.08. The stock has a market cap of $15.09 billion, a P/E ratio of 16.03, a P/E/G ratio of 1.23 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same period in the prior year, the firm earned $5.24 earnings per share. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $313.91, for a total value of $1,130,076.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $40,808.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $313.91, for a total value of $1,130,076.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $40,808.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Raymond Dwek sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the transaction, the director now owns 1,750 shares of the company’s stock, valued at $569,362.50. The disclosure for this sale can be found here. Insiders sold a total of 114,522 shares of company stock worth $37,671,474 in the last three months. Insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.